

Metabolic imaging across scales reveals distinct prostate cancer phenotypes

Nikita Sushentsev^{1†*}, Gregory Hamm^{2†}, Lucy Flint², Daniel Birtles², Aleksandr Zakirov³, Jack Richings², Stephanie Ling², Jennifer Y. Tan², Mary A. McLean^{1,4}, Vinay Ayyappan¹, Ines Horvat Menih¹, Cara Brodie⁴, Jodi L. Miller⁴, Ian G. Mills^{5,6,7,8}, Vincent J. Gnanapragasam^{9, 10,11}, Anne Y. Warren¹², Simon T. Barry¹³, Richard J.A. Goodwin^{2††}, Tristan Barrett^{1††}, Ferdia A. Gallagher^{1††}

¹ Department of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK

² Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK

³ Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

⁴ Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK

⁵ Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK

⁶ Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK

⁷ Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway

⁸ Department of Clinical Science, University of Bergen, Bergen, Norway

⁹ Department of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

¹⁰ Division of Urology, Department of Surgery, University of Cambridge, Cambridge, UK

¹¹ Cambridge Urology Translational Research and Clinical Trials Office, Cambridge Biomedical Campus, Addenbrooke's Hospital, Cambridge, UK

¹² Department of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

¹³ Bioscience, Discovery, Oncology R&D, AstraZeneca, Cambridge, UK

† These authors contributed equally

†† These authors jointly supervised the work

*Corresponding author. Email: ns784@medschl.cam.ac.uk

Supplementary Information file including:

Supplementary Table 1

Extended Data Figures 1-6

exp_peak	interval_width_da	compound_name
87.0088	0.00051129959854279	Pyruvate
89.0246	0.00052314529990838	Lactate
103.0036	0.00060529199649295	Malonate
112.9877	0.00066396247220268	Oxaloacetate
115.0035	0.0006758082859335	Fumarate
117.0194	0.00068765446259533	Succinate
125.0972	0.00073512268198073	Octanoic acid
131.0351	0.00077001646214114	Glutarate
133.0145	0.00078164818512505	Malate
145.0144	0.00085216473715377	alpha-Ketoglutarate
152.9962	0.00089906909218485	Succinate
153.1287	0.0008998474800137	Decanoic acid
166.9755	0.00098121705471499	Phosphoenolpyruvate
173.0093	0.0010166739553483	cis-Aconitate;Citrate
179.0561	0.001052207884598	Glucose
189.004	0.0011106654522308	Oxalosuccinate
191.02	0.001122512497858	Citrate
208.9846	0.0025771426214618	cis-Aconitate
215.0325	0.0012636201084888	Glucose
224.9801	0.001322076059239	Oxalosuccinate
227.2014	0.0013351295196173	Tetradecanoic acid
241.012	0.0014162866034297	Glucose 1-phosphate
246.9398	0.0014511207514829	Glycerate 1,3-biphosphate
253.2173	0.0014880098153043	Palmitoleic acid
281.2482	0.0016527310219772	Oleic acid
283.2654	0.0016645846906727	Octadecanoic acid
284.056	0.0016692306908794	S-Acetyldihydroipoamide-E
291.2099	0.0017112699781592	Hexadecanoic acid
317.2244	0.0018641420160179	Oleic acid
319.2406	0.0018759897287168	Octadecanoic acid
398.3282	0.0023407415183669	L-Palmitoylcarnitine

Supplementary Table 1. The list of KEGG glycolysis, TCA cycle, and fatty acid biosynthesis metabolites used for DESI-MSI-derived metabolic pathway enrichment analysis in the secondary cohort.